TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

GlobeNewswire Inc. Logo GlobeNewswire Inc. By James (Josh) Wilson
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Faruqi & Faruqi is investigating potential securities claims against aTyr Pharma after the company's stock dropped 83.25% following disappointing clinical trial results for its drug Efzofitimod, which failed to demonstrate significant steroid reduction in patients.

Insights
ATYR   negative

Stock price dropped dramatically by 83.25% after clinical trial results showed minimal efficacy of Efzofitimod in steroid dose reduction, leading to potential securities lawsuit